We are thrilled to have been shortlisted as a finalist for the 2024 Communiqué Awards in the Excellence in Communicating and Using Data category for our submission, First Consensus Recommendations for Holistic Care in Hereditary ATTR Amyloidosis. Through this project with Alnylam Pharmaceuticals, we developed the first published recommendations to recognize the value of the patient community in advocating for the needs of patients with ATTRv amyloidosis, and to call for a major shift in the current approach to its management. These recommendations were published in BMJ Open, a peer-reviewed, open access journal with wide dissemination to a global audience. The Communique Awards “recognize, reward and commend excellence and best practices in medical affairs and healthcare communications.” For more information about the awards, visit https://buff.ly/4eEprBO #CommuniqueAwards2024 #healthcarecomms #amyloidosis #medicalaffairs #patientadvocacy #ATTRv #patientcommunity
Lumanity’s Post
More Relevant Posts
-
Many pharmaceutical companies are turning to patient support programs to ensure their products reach their full potential and improve patient outcomes. When deploying PSPs across Europe, they may encounter a unique set of challenges related to navigating the diverse healthcare landscape of the region. In our latest case study, we present how Sciensus successfully supported a US biotech in deploying a European patient support program for a pioneering therapy targeting an ultra-rare paediatric disorder. To learn more, visit: https://lnkd.in/eXPK7Vqd #PSP #PatientSupportProgram #RareDiseases #OrphanDrugs
To view or add a comment, sign in
-
-
Weekly Rare Update Partnerships and collaborations across sectors have the potential to create real change in all areas of healthcare, especially in rare diseases. The challenges associated with getting a diagnosis are amplified by NHS constraints, lack of awareness and an unclear diagnosis referral pathway. This ABPI report showcases several partnership examples and provides a simple framework or practical actions to build collaboration and lead to greater innovation in health. For the full report visit The Association of the British Pharmaceutical Industry (ABPI) https://lnkd.in/ekfSrXEY #innovation #collaboration
To view or add a comment, sign in
-
-
Digital Health / Precision Medicine/ Venture Partner / ex International Pharma Executive, Human Geneticist
Great summary thought piece of industry trends in #medtech, #personalizedmedicine, #digitaltherapeutics, #PDURS, from Click's CEO David Benshoof Klein and CMO Shaheen E Lakhan, MD, PhD, FAAN highlighting the impactful role of Click Therapeutics, Inc. therapeutics in developing and bringing to market rigorous, evidenced-based, engaging digital interventions that are easily accesible and improve outcomes. Their pioneering work in PDTx continues and this article helps shred light to it and the promise of PDURS for uniquely / optimally deigned Device+Drug Combo development. Cant wait to see who from Pharma steps up to this innovation! .... The GLP1 space seems well suited to a high tech, engaging and efficacious digital patient solution +drug!
In a recent MedTech Insight article, Click CEO David Benshoof Klein and CMO Shaheen E Lakhan, MD, PhD, FAAN highlighted Click's strategic priorities, new developments in our pipeline, and the transformative potential of the FDA's latest Prescription Drug Use-Related Software (PDURS) draft guidance on #DigitalTherapeutics. Insights included: - The FDA’s “Prescription Drug Use-Related Software” draft guidance represents a pivotal opportunity for Click, as it helps clarify how combining our software as a medical device (#SaMD) with pharmacotherapy could enable pharma manufacturers to update drug labels with additional clinically meaningful benefit claims. - Leveraging digital interventions to offer personalized treatment not only improves outcomes across various health metrics like cognitive function and cardiovascular risk but also aligns with pharma's evolving demand for tailored solutions, potentially reshaping patient management and payer agreements, particularly in the GLP-1 therapy space. - Click continues to thrive by prioritizing rigorous clinical trials and demonstrating substantial clinical benefits, contrasting with competitors who faced challenges in meeting stakeholder expectations. Read more about Click's approach and our views on the future of digital therapeutics here: https://lnkd.in/epPgkPF9 #DTx #HealthInnovation #MedicalTechnology #ClinicalResearch
To view or add a comment, sign in
-
-
Helping pharma companies design and implement ethical and compliant global early access solutions that minimize risk and accelerate future growth
The European Federation of Pharmaceutical Industries and Associations (EFPIA) published the 2023 Patient W.A.I.T. data last month, and the results are consistent with previous years. Consistent in that depending on where rare disease patients live in Europe, their access to new therapeutics varies greatly despite a centralized approval in most of those countries. It also points to the importance of companies having early access programs in place to meet this unmet medical need. There remains much work to do.
Early access to medicines: A picture is worth a thousand words. John Lagus, founder of Bluestem Pharma Consulting, LLC joins our Industry Insights panel to share his vast experience in early access to medicines, which is sometimes referred to as expanded access, managed access, compassionate use or named patient supply. https://lnkd.in/eD5hcm5S #IndustryInsights #EarlyAccess #AccessToMedicines
To view or add a comment, sign in
-
-
IQWiG Implements Updated Methods in German Cost-Benefit Assessments: Version 7.0 in Effect The Institute for Quality and Efficiency in Health Care (IQWiG) has released General Methods version 7.0, which includes updates to adapt to the changing healthcare landscape and improve transparency. Stakeholder input was invited and led to revisions and improvements. Key changes include revisions to cost-benefit assessments, streamlining the process, and narrowing the focus. IQWiG also integrates a new methodological framework to address real-world evidence (RWE) and the review of indication registries, enhancing decision-making processes. These updates reflect IQWiG's commitment to evidence-based healthcare. For more details please click the link! https://lnkd.in/d6fqey7F #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
To view or add a comment, sign in
-
Welcome to day 107 of the year folks, there are 259 days remaining in 2024. Today, we're sharing the main aim of diagnostic device development, empowering healthcare providers to detect diseases sooner and save lives. At GONEP Pharmaceuticals our main goal is to come up with a product that will revolutionize access to healthcare. Our portable device -Clinic at hand- promises advancements in diagnosis and general patient care. As healthcare professionals, we have witnessed firsthand the importance of early diagnosis in patient care. 🌐gonepharm.com #Gonep #Gonepharm #Pharmaceuticals #EarlyDiagnosis #PatientCare
To view or add a comment, sign in
-
-
In today's rapidly evolving pharmaceutical landscape, patient engagement has never been more crucial and at OPEN Health, we're committed to helping you navigate this complex landscape successfully. Learn how patient engagement can combat the nocebo effect and empower patients in our latest whitepaper https://hubs.la/Q022Gc8q0 #Patientengagement #noceboeffect #patientsaspartners
OPEN Health | Navigating the nocebo effect
openhealthgroup.com
To view or add a comment, sign in
-
In a recent MedTech Insight article, Click CEO David Benshoof Klein and CMO Shaheen E Lakhan, MD, PhD, FAAN highlighted Click's strategic priorities, new developments in our pipeline, and the transformative potential of the FDA's latest Prescription Drug Use-Related Software (PDURS) draft guidance on #DigitalTherapeutics. Insights included: - The FDA’s “Prescription Drug Use-Related Software” draft guidance represents a pivotal opportunity for Click, as it helps clarify how combining our software as a medical device (#SaMD) with pharmacotherapy could enable pharma manufacturers to update drug labels with additional clinically meaningful benefit claims. - Leveraging digital interventions to offer personalized treatment not only improves outcomes across various health metrics like cognitive function and cardiovascular risk but also aligns with pharma's evolving demand for tailored solutions, potentially reshaping patient management and payer agreements, particularly in the GLP-1 therapy space. - Click continues to thrive by prioritizing rigorous clinical trials and demonstrating substantial clinical benefits, contrasting with competitors who faced challenges in meeting stakeholder expectations. Read more about Click's approach and our views on the future of digital therapeutics here: https://lnkd.in/epPgkPF9 #DTx #HealthInnovation #MedicalTechnology #ClinicalResearch
To view or add a comment, sign in
-
-
British Columbia's Biosimilars Initiative has successfully saved about $732 million over five years by transitioning over 40,000 patients from reference biologics to biosimilars, without compromising health outcomes. This incredible achievement was not merely due to changing prescriptions, but thanks to a comprehensive program for patients and physicians. Key aspects of the initiative included: 🔄 6-month transition period 📜 A requirement for a new prescription from a prescriber for the switch 💬 Support fees for prescribers and pharmacists assisting patients 📝 Patient lists for prescribers 🔍 Consultations with patient groups, clinicians, professional bodies, insurers, and drug sponsors 📚 Educational and support tools for patients and healthcare providers 📢 Coordinated communications 📊 Monitoring biosimilar utilization ❗Exceptional coverage for patients unable to switch for clinical reasons ⛔ Delisting reference biologics after the transition period With adoption rates of 91%-95% within 24 months, BC's model exemplifies effective biosimilar adoption for cost savings and improved patient care, setting a precedent for other regions. Explore how we integrate patient insights into clinical trials and healthcare solutions: >> https://lnkd.in/dtgXSjVm >> https://lnkd.in/dc4kXmjw #biosimilars #patients #clinicalresearch #clinicaltrials #healthcare #biotech
To view or add a comment, sign in
-
-
👨⚕️💼 Tap into Expertise with MHN's Physicians Panel! 💊💡 Plan your project here: https://lnkd.in/er-_cxKu Attention pharmaceutical brands and healthcare innovators! 📣 Are you searching for a reliable platform to test and refine your new marketing strategies, medicines, and products? Look no further than MHN's esteemed Physicians Panel! Our panel comprises a diverse network of medical professionals from various specialties and backgrounds, offering unparalleled expertise and insights into the ever-evolving healthcare landscape. Whether you're launching a new medication, exploring innovative treatment options, or fine-tuning your marketing campaigns, our Physicians Panel provides a robust platform to gather valuable feedback and make informed decisions. With MHN, you can engage with leading physicians, clinicians, and healthcare experts who are at the forefront of medical advancements and patient care. Our panelists offer invaluable perspectives on efficacy, safety, and patient outcomes, helping you navigate regulatory requirements and market dynamics with confidence. Don't miss out on this opportunity to collaborate with top-tier healthcare professionals and leverage their expertise to drive innovation and success in your industry. Reach out to MHN today to learn more about how our Physicians Panel can help you test new marketing strategies, medicines, and products and stay ahead in the competitive healthcare market! #MHNInsights #PhysiciansPanel #HealthcareInnovation #Pharmaceuticals #MedicalExperts 💉 #RepresentativeSamples #MarketResearch 🚀🔍 #QualitativeResearch #QuantitativeResearch #MHN #MHNInsights
MHN
To view or add a comment, sign in